Codexis/CDXS

$4.16

30%
-
1D1W1MYTD1YMAX

About Codexis

Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.

Ticker

CDXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephen Dilly

Employees

248

Headquarters

Redwood city, United States

Codexis Metrics

BasicAdvanced
$211.59M
Market cap
-
P/E ratio
-$1.21
EPS
1.89
Beta
-
Dividend rate

What the Analysts think about Codexis

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
44.23% upside
High $10.00
Low $3.00
$4.16
Current price
$6.00
Average price target

Codexis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-379.34% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$9.2M
-56.81%
Net income
$-34.9M
203.48%
Profit margin
-379.34%
602.61%

Codexis Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 54.18%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.34
-$0.17
-$0.50
-
Expected
-$0.23
-$0.31
-$0.21
-$0.32
-$0.12
Surprise
-38.19%
9.94%
-20.47%
54.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Codexis stock

Buy or sell Codexis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing